Remarkably, the population of mesothelin-positive CD45dim/SSC-Alow myeloblasts ranged from 3.73% to 22.2% in 7 out of 22 AML patients at diagnosis, while the remaining 15 patients had <1.57% mesothelin-positive myeloblasts (Figure 1B,E), as confirmed via flow cytometry. The gene discussed is MSLN; the disease is acute myeloid leukemia.